Boryung Commences Global Supply of Anticancer Drug Alimta, Elevating CDMO Presence
Boryung Corp. announced Monday the successful commencement of its global supply of the vital **anticancer drug Alimta** to Lotus Pharmaceuticals. This landmark event signifies Boryung’s first major international **Contract Development and Manufacturing Organization (CDMO)** project, solidifying its position as a key player in the global pharmaceutical market.
The strategic partnership began with a comprehensive **CDMO agreement** signed between Boryung and Lotus Pharmaceuticals in 2024. Prior to initiating shipments, Boryung meticulously completed all necessary quality verifications, secured regulatory approvals, and finalized production preparations at its advanced, **EU-GMP-certified Yesan Campus**. This rigorous process underscores Boryung’s commitment to delivering high-quality, compliant pharmaceutical products worldwide.
Expanding Oncology Portfolio and Manufacturing Expertise
Boryung has strategically bolstered its **oncology portfolio** through a series of significant acquisitions in recent years. This expansion began with Gemzar in 2020 and subsequently included key original-brand businesses, notably the acquisition of Alimta. Further strengthening its commitment to cancer treatment solutions, Boryung also acquired both domestic and global business rights for Taxotere last year, enhancing its comprehensive offerings in oncology.
The company successfully executed the transfer and internalization of Alimta’s complex **manufacturing technology** within its state-of-the-art facilities following the acquisition of the product’s domestic business rights. A notable innovation involved converting the Alimta product from a powder to a more efficient liquid formulation. This strategic enhancement not only improved the drug’s overall profitability but also significantly boosted Boryung’s competitive edge in the **global anticancer drug market**.
Driving Global CDMO Growth and Supply Chain Resilience
Looking ahead, Boryung aims to significantly expand its global **CDMO business**. By leveraging its proven capabilities in advanced manufacturing technology transfer and sophisticated formulation development, the company plans to offer more than just basic contract manufacturing. Boryung is poised to deliver integrated, end-to-end solutions for pharmaceutical development and production.
Kim Sung-jin, a representative of Boryung, emphasized the company’s vision: “We are committed to establishing Boryung as a trusted global supply partner. Our strong foundation is built upon our extensive experience in internalizing original-product manufacturing technologies, robust quality management systems, and a world-class production infrastructure.”
Kim further highlighted the critical importance of reliable pharmaceutical production and stable supply capabilities, especially in an era marked by recurrent disruptions across global supply chains. Boryung’s strategic initiatives are designed to ensure consistent access to essential medicines, contributing to global health security.
jwjeon7625
